Log in

Relevant bibliographies by topics / Sirolimus-eluting stent (SES)

Contents

Journal articles
Dissertations / Theses
Book chapters

Academic literature on the topic 'Sirolimus-eluting stent (SES)'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sirolimus-eluting stent (SES).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sirolimus-eluting stent (SES)"

1

Hu, Patrick P., and Ehtisham Mahmud. "Sirolimus Eluting Stents." Clinical Medicine Insights: Therapeutics 2 (January 2010): CMT.S2094. http://dx.doi.org/10.4137/cmt.s2094.

Full text

Abstract:

The sirolimus-eluting stent (SES) Cypher was the first commercially available drug-eluting stent. The use of this stent has resulted in significantly lower rates of restenosis and lesion revascularization compared to bare metal stents and balloon angioplasty. In this review, angiographic and clinical outcomes in patients treated with SES are compared to those treated with bare metal stents and other drug-eluting stents. Furthermore, efficacy and safety outcomes of SES in complex lesions (left main stenosis, bifurcation lesions, chronic total occlusions, long lesions and small vessels) and high

APA, Harvard, Vancouver, ISO, and other styles

2

Adriano Dourado. "Comparative Clinical Performance of Two Types of Drug-Eluting Stents with Abluminal Biodegradable Polymer Coating: Five-Year Results of the DESTINY Randomized Trial." Revista Científica Hospital Santa Izabel 6, no. 3 (2022): 159–64. http://dx.doi.org/10.35753/rchsi.v6i3.332.

Full text

Abstract:

Introduction and Objectives: The Stents Coated with the Biodegradable Polymer on Their Abluminal Faces and Elution of Sirolimus versus Biolimus Elution for the Treatment of de Novo Coronary Lesions - DESTINY Trial is a non-inferiority randomized study that compared the InspironTM sirolimus-eluting stent (SES) with the control BiomatrixTM Flex biolimus-eluting stent (BES). Previous reports in the first year showed similar outcomes for both stents, in clinical, angiographic, optical coherence tomography, and intravascular ultrasound assessments. The present analysis aims to compare the clinical

APA, Harvard, Vancouver, ISO, and other styles

3

Almasood, Ali S., Xavier Freixa, Sohail Q. Khan, Peter H. Seidelin, and Vladimír Džavík. "Stent Fracture after Everolimus-Eluting Stent Implantation." Cardiology Research and Practice 2011 (2011): 1–5. http://dx.doi.org/10.4061/2011/320983.

Full text

Abstract:

Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events. Recently, stent fracture (SF) has emerged as a potential mechanism of DES failure that is associated with ISR. Stent fracture is strongly related to stent type, and prior reports suggest that deployment of sirolimus eluting stents (SES) may be associated with a higher risk of SF compared to other DES. Everolimus eluting stents (EESs) represent a new generation

APA, Harvard, Vancouver, ISO, and other styles

4

Leshkevich, Ch F., E. V. Kovsh, G. A. Sergeev, A. B. Maximchik, D. N. Boncevich, and I. E. Adzerikho. "ASSESSMENT OF INTERVENTION TREATMENT OF UNSTABLE ANGINA OF PATIENTS OF DIABETES MELLITUS TYPE 2." Health and Ecology Issues, no. 4 (December 28, 2008): 34–39. http://dx.doi.org/10.51523/2708-6011.2008-5-4-6.

Full text

Abstract:

The purpose of the study is a comparative assessment of the immediate and long-term results using Sirolimus - Eluting Stents (SES) and Bare-Metal Stent (BMS) in patients with unstable angina and diabetes mellitus type 2.

APA, Harvard, Vancouver, ISO, and other styles

5

Jimba, Takahiro, Takehiro Hashikata, Masashiro Matsushita, and Masao Yamasaki. "Repetitive restenosis in a biodegradable polymer sirolimus-eluting stent with hypersensitivity reaction: a case report." European Heart Journal - Case Reports 4, no. 1 (2020): 1–5. http://dx.doi.org/10.1093/ehjcr/ytaa001.

Full text

Abstract:

Abstract Background Hypersensitivity reaction is a classic cause of in-stent restenosis (ISR) in coronary stents, typically reported in bare-metal stents and first-generation drug-eluting stents. Biodegradable polymer sirolimus-eluting stent (BP-SES) was developed with the concept of biocompatibility, and there has been no report of ISR of BP-SES with hypersensitivity reaction. Case summary An 81-year-old woman presented with ST-elevation acute inferior myocardial infarction. Primary percutaneous coronary intervention was performed for the culprit lesion in the left circumflex artery with a pe

APA, Harvard, Vancouver, ISO, and other styles

6

Koppara, Tobias, Michael Joner, Gerd Bayer, Kristin Steigerwald, Tobias Diener, and Eric Wittchow. "Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation." Thrombosis and Haemostasis 107, no. 06 (2012): 1161–71. http://dx.doi.org/10.1160/th12-01-0043.

Full text

Abstract:

SummaryBiodegradable stent coatings were recently introduced as a potential solution to overcome sustained inflammatory responses observed with permanent polymer-based drug-eluting stents. In a preliminary study, selected biodegradable or permanent polymer-based sirolimus-eluting stent (SES) formulations were screened for effectiveness in comparison to bare metal stents (BMS) at 28 days. Subsequently, the most favourable SES formulation was compared to commercially available SES (CypherTM) at 28,90 and 180 days to investigate the histopathologic response as well as tissue, blood and organ phar

APA, Harvard, Vancouver, ISO, and other styles

7

Chong, Eric, Kian Keong Poh, Shen Liang, Xu Min Hou, and Huay Cheem Tan. "Eighteen-Month Clinical Safety and Efficacy Outcomes of Sirolimus-, Paclitaxel and Zotarolimus-drug Eluting Stents in Diabetic Patients Undergoing Percutaneous Coronary Intervention for Complex Coronary Artery Stenosis." Annals of the Academy of Medicine, Singapore 39, no. 5 (2010): 381–84. http://dx.doi.org/10.47102/annals-acadmedsg.v39n5p381.

Full text

Abstract:

Introduction: This was a single centre registry study on clinical efficacy and safety of drug-eluting stent (DES) in diabetic patients undergoing percutaneous coronary intervention (PCI) for complex coronary lesions. Materials and Methods: A total of 288 diabetic patients who underwent elective PCI between September 2003 and June 2006 in our centre were enrolled and followed-up for 18 months. Among them, 79 (27.4%) patients received sirolimus-eluting stent (SES), 138 (47.9%) paclitaxel-eluting stent (PES) and 71 (24.7%) zotarolimus-eluting stent (ZES). The endpoints were major adverse cardiac

APA, Harvard, Vancouver, ISO, and other styles

8

Sperling, Christian, Matthias W. Waliszewski, Behrouz Kherad, and Florian Krackhardt. "Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries." Therapeutic Advances in Cardiovascular Disease 13 (January 2019): 175394471982633. http://dx.doi.org/10.1177/1753944719826335.

Full text

Abstract:

Background: Polymer-free drug-eluting stents (DES) without permanent-polymer coating may be associated with rapid vessel healing, providing a rationale to reduce dual-antiplatelet therapy (DAPT). The aim of the current study was to compare vessel healing of a polymer-free sirolimus-eluting stent (PF-SES), its bare metal stent (BMS) analogue to a permanent polymer-based sirolimus-eluting stent (SES) with proven effectiveness in porcine coronary arteries. Material and methods: An ultrathin-strut cobalt–chromium PF-SES, its BMS analogue and an SES with a permanent polymer were used to study vesse

APA, Harvard, Vancouver, ISO, and other styles

9

Jakobsen, Lars, Evald H. Christiansen, Phillip Freeman, et al. "Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial." Circulation 143, no. 22 (2021): 2155–65. http://dx.doi.org/10.1161/circulationaha.120.052766.

Full text

Abstract:

Background: Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ antibody–coated Combo stent (DTS) was designed to further improve early healing. This study aimed to investigate whether the DTS is noninferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population. Methods: The SORT OUT X (Combo Stent Versus Orsiro Stent) trial, was a large-scale, randomized, multicenter, single-blind, 2-arm, noninferiority trial with registry-based follow-up. The primary end point target lesion failure was a co

APA, Harvard, Vancouver, ISO, and other styles

10

Otsuka, Fumiyuki, Masataka Nakano, Saami K. Yazdani, Elena Ladich, Frank D. Kolodgie, and Renu Virmani. "Pathology of First-generation Drug-eluting Stents in Humans." Asia Pacific Cardiology 3, no. 1 (2011): 52. http://dx.doi.org/10.15420/apc.2011:3:1:52.

Full text

Abstract:

First-generation sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) have dramatically reduced restenosis, although concern still exists about the long-term safety of this technology since observational studies have shown a steady increase in the rate of late stent thrombosis (LST), an infrequent but catastrophic complication. Although the mechanisms of LST are multifactorial, our laboratory has demonstrated that delayed arterial healing accompanied by poor endothelialisation is the primary pathogical substrate underlying this event. Delayed arterial healing is associated with p

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Sirolimus-eluting stent (SES)"

1

Borchardt, Annette. "Behandlung der koronaren Herzerkrankung mit Ballondilatation und Implantation von Sirolimus-Drug-Eluting-Stents : klinische und angiographische Ergebnisse eines nicht selektionierten Krankengutes /." Regensburg, 2007. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000253168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Sirolimus-eluting stent (SES)"

1

Caixeta, Adriano, Philippe Généreux, George Dangas, and Roxana Mehran. "In-stent restenosis in the drug-eluting stent era." In Oxford Textbook of Interventional Cardiology. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199569083.003.028.

Full text

Abstract:

For the last two decades, restenosis has been considered the most significant problem in interventional cardiology. Drug-eluting stents (DES) have reduced rates of restenosis and target lesion revascularization (TLR) by 50–90% compared with bare-metal stents (BMS) across all lesion and patient subsets. However, a small number of patients have in-stent restenosis (ISR) after DES treatment. DES efficacy has been limited by suboptimal polymer biocompatibility, suitability of pharmacological agents, suboptimal in vivo pharmacokinetic properties, and local drug resistance and toxicity. The first tw

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!